Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02640170 · ClinicalTrials.gov registry record
Intraoperative Imaging With ICG Registry
A clinical trial, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- 291
- Enrollment target
NCT02640170: Completed study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT02640170 is a clinical trial that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 291 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02640170 has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- 291 participants
- Enrollment target
Study Summary
The purpose of this registry is to monitor the rate of recurrence in patients who undergo cancer surgery.
Interventions
- OTHER Registry
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 291 participants |
| Start Date | 2016-07 |
| Est. Completion | 2020-02 |
What the finished NCT02640170 record still lists
NCT02640170 is an observational study that tracks outcomes without assigning an intervention. The registered 291 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Registry is the first listed.
NCT02640170 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02640170 about?
NCT02640170 is a clinical study titled "Intraoperative Imaging With ICG Registry". The purpose of this registry is to monitor the rate of recurrence in patients who undergo cancer surgery.
What is the current status of trial NCT02640170?
This trial is currently completed. The enrollment target is 291 participants. The study started on 2016-07. Estimated completion is 2020-02.
What interventions are being tested in trial NCT02640170?
The interventions under investigation include: Registry (OTHER).
Who is sponsoring clinical trial NCT02640170?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02074839 · 291 participants · Phase 1
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
- NCT03769766 · 291 participants · Phase 3
Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance
- NCT06563479 · 291 participants · Phase 3
A Study Comparing Personalized Radiation Therapy With Standard Radiation Therapy in People With HPV-Positive Throat Cancer
- NCT04429542 · 292 participants · Phase 1
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia